A review of the clinical efficacy profile of copolymer 1: New U.S. phase III trial data

Journal of Neurology

Volumn 243, Issue SUPPL. 1, 1996, Pages

  Johnson, Kenneth P ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Copolymer 1; Experimental allergic encephalomyelitis; Interferon beta; Multiple sclerosis

Indexed keywords

GLATIRAMER; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; CLINICAL TRIAL; CONFERENCE PAPER; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; SUPPRESSOR CELL;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 0029876990     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf00873695     Document Type: Article

References (15)

1. Abramsky O, Teitelbaum D, Arnon R (1977) Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and acute disseminated encephalomyelitis: preliminary report. J Neurol Sci 31:433-438
2. Arnon R (1981) Experimental allergic encephalomyelitis - susceptibility and suppression. Immunol Rev 55:5-30
3. Arnon R, Teitelbaum D (1980) Desensitization of experimental allergic encephalomyelitis with synthetic peptide analogues. In: Davison AN, Cuzner ML (eds) The suppression of experimental allergic encephalomyelitis and multiple sclerosis. Academic Press, New York, pp 105-117
4. Bornstein MB, Miller A, Teitelbaum D, et al (1982) Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol 11:317-319
5. Bornstein MB, Miller A, Slagle S, et al (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317:408-414
6. Bornstein MB, Miller A, Slagle S, et al (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41:533-539
7. Frances GS, Evans AC, Arnold DL (1995) Neuroimaging in multiple sclerosis. In: Antel JP (ed) Multiple sclerosis neurologic clinics, vol 13. Saunders, Philadelphia, pp 147-171
8. Hauser SL, Dawson DM, Lehrich JR, et al (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308:173-180
9. Hohlfeld R, Lucas K (1995) Cytokine networks in multiple sclerosis. Neurology 45 [Suppl 6]:S1-S55
10. Johnson KP, Brooks BR, Cohen JA, et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276
11. Kurtzke JF (1955) A new scale for evaluating disability in multiple sclerosis. Neurology 5:580-583
12. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
13. Milo R, Panitch H (1995) Additive effects of copolymer-1 and Interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 61: 185-193
14. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
15. Weinshenker BG, Bass B, Rice G, et al (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112:1419-1428